Mineralys Therapeutics, Inc. (MLYS)

Mineralys Therapeutics, Inc.'s stock price increased significantly over the past six months, driven by positive clinical trial results for lorundrostat. The FDA accepted the New Drug Application for lorundrostat for hypertension, with a target date of December 22, 2026. However, a Phase 2 trial for obstructive sleep apnea did not demonstrate a clinically meaningful difference relative to placebo. As of April 8, 2026, the stock price was $27.76, with a 52-week range of $11.77 to $47.65.

Mineralys Therapeutics, Inc. is not subject to traditional demand seasonality for its products and services. The demand for lorundrostat, once approved, would be driven by the prevalence of the targeted medical conditions rather than seasonal fluctuations.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for diseases driven by abnormally elevated aldosterone, particularly cardiorenal conditions. Their lead product candidate, lorundrostat, is being developed for uncontrolled and resistant hypertension, as well as chronic kidney disease and obstructive sleep apnea. The company was formed in 2019 and licensed lorundrostat in 2020.

Mineralys Therapeutics, Inc. is headquartered in Radnor, Pennsylvania, United States. The company's focus for developing medicines to target diseases driven by dysregulated aldosterone is in the United States.

Mineralys Therapeutics has a positive brand reputation due to promising clinical trial results and positive analyst sentiment. The company has a "Moderate Buy" consensus rating from analysts, with a consensus price target of $49.14. Key events contributing to its reputation include successful clinical trials for lorundrostat and the FDA's acceptance of the NDA. In March 2026, the company also announced the appointment of Jeffrey A. Munsie as Chief Legal Officer.

Mineralys Therapeutics, Inc. has significant institutional ownership, with major holders including Catalys Pacific, LLC, and Ra Capital Management, L.p. Srinivas Akkaraju is the largest individual shareholder. Institutional shareholders hold 107.23% of the stock, while Mineralys Therapeutics insiders hold 46.90%.